The protection of novel 2-arylethenylquinoline derivatives against impairment of associative learning memory induced by neural Aβ in C. elegans Alzheimer’s disease model

Neurochemical Research

Volumn 42, Issue 11, 2017, Pages 3061-3072

  He, Qidi ^a   Huang, Guan ^a   Chen, Yixin ^a   Wang, Xiaoqin ^a   Huang, Zhishu ^a   Chen, Zuanguang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

2 Arylethenylquinoline derivatives; Alzheimer s disease; Associative learning memory; Caenorhabditis elegans; Chemotaxis

Indexed keywords

2 ARYLETHENYLQUINOLINE DERIVATIVE; AMYLOID BETA PROTEIN; BETA ACTIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 16.1; HEAT SHOCK PROTEIN 16.2; NEUROPROTECTIVE AGENT; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; QUINOLINE;

ALZHEIMER DISEASE; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; FOOD DEPRIVATION; LEARNING; LIMIT OF QUANTITATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATE DEPENDENT LEARNING; ANIMAL; ASSOCIATIVE LEARNING; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; MEMORY; PHYSIOLOGY; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ASSOCIATION LEARNING; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; MEMORY; NEUROPROTECTIVE AGENTS; QUINOLINES;

EID: 85021778028     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-017-2339-0     Document Type: Article

References (48)

1. Wimo A, Winblad B, Jonsson L (2010) The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 6(2):98–103
2. Rios JA, Cisternas P, Arrese M, Barja S, Inestrosa NC (2014) Is Alzheimer’s disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol 121:125–146
3. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S (2002) The public health impact of Alzheimer’s disease 2000–2050: potential implication of treatment advances. Annu Rev Publ Health 23:213–231
4. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377(9770):1019–1031
5. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C (2006) A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry 21(1):17–28
6. Mucke L (2009) Alzheimer’s disease. Nature 461(7266):895–897
7. Golde TE, Schneider LS, Koo EH (2011) Anti-aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron 69(2):203–213
8. Leon R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev 33(1):139–189
9. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ (1997) Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 3(1):67–72
10. Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, Younkin S, Duff K, Hardy J, Hutton M (1998) Increased Aβ42 (43) from cell lines expressing presenilin 1 mutations. Ann Neurol 43(2):256–258
11. Hardy J, Selkoe DJ (2002) Medicine—the amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356
12. Wang H, Guo X, Jiang S, Tang G (2013) Automated synthesis of [18 F] Florbetaben as Alzheimer’s disease imaging agent based on a synthesis module system. Appl Radiat Isot 71(1):41–46
13. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K (2001) Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123(50):12740–12741
14. 18F-labeled styryltriazole and resveratrol derivatives for β-amyloid plaque imaging. J Med Chem 55(2):883–892
15. Jiang HL, Wang X, Huang L, Luo ZH, Su T, Ding K, Li XS (2011) Benzenediol-berberine hybrids: multifunctional agents for Alzheimer’s disease. Bioorg Med Chem 19(23):7228–7235
16. Oz M, Lorke DE, Petroianu GA (2009) Methylene blue and Alzheimer’s disease. Biochem Pharmacol 78(8):927–932
17. Mancino AM, Hindo SS, Kochi A, Lim MH (2009) Effects of clioquinol on metal-triggered amyloid-β aggregation revisited. Inorg Chem 48(20):9596–9598
18. Freeman SE, Dawson RM (1991) Tacrine: a pharmacological review. Prog Neurobiol 36(4):257–277
19. Wang XQ, Xia CL, Chen SB, Tan JH, Ou TM, Huang SL, Li D, Gu LQ, Huang ZS (2015) Design, synthesis, and biological evaluation of 2-arylethenylquinoline derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem 89:349–361
20. Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V (2007) Insight into the kinetic of amyloid β (1–42) peptide self-aggregation: elucidation of inhibitors’ mechanism of action. ChemBioChem 8(17):2152–2161
21. Davalos A, Gomez-Cordoves C, Bartolome B (2004) Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J Agric Food Chem 52(1):48–54
22. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77(1):71–94
23. Sulston JE, White JG (1980) Regulation and cell autonomy during postembryonic development of Caenorhabditis elegans. Dev Biol 78(2):577–597
24. Avery L, Horvitz HR (1989) Pharyngeal pumping continues after laser killing of the pharyngeal nervous system of C. elegans. Neuron 3(4):473–485
25. Link CD (1995) Expression of human β-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92(20):9368–9372
26. Dosanjh LE, Brown MK, Rao G, Link CD, Luo Y (2010) Behavioral phenotyping of a transgenic Caenorhabditis elegans expressing neuronal amyloid-β. J Neurosci 19(2):681–690
27. Gutierrez-Zepeda A, Santell R, Wu ZX, Brown M, Wu YJ, Khan I, Link CD, Zhao BL, Luo Y (2005) Soy isoflavone glycitein protects against β amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci 6:54
28. Wu YJ, Wu ZX, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26(50):13102–13113
29. Abbas S, Wink M (2010) Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 17(11):902–909
30. Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, Doglia SM, De Luigi A, Salmona M (2010) Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 40(2):424–431
31. Dostal V, Roberts CM, Link CD (2010) Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of β-amyloid peptide toxicity. Genetics 186(3):857–866
32. Sangha JS, Sun X, Wally OSD, Zhang K, Ji X, Wang Z, Wang Y, Zidichouski J, Prithiviraj B, Zhang J (2012) Liuwei Dihuang (LWDH), a traditional Chinese medicinal formula, protects against β-amyloid toxicity in transgenic Caenorhabditis elegans. PLoS One 7(8):e43990
33. Zhang W, Zhi D, Ren H, Wang D, Wang X, Zhang Z, Fei D, Zhu H, Li H (2016) Shengmai formula ameliorates pathological characteristics in AD C. elegans. Cell Mol Neurobiol 36(8):1291–1302
34. Hobert O, Bulow H (2003) Development and maintenance of neuronal architecture at the ventral midline of C. elegans. Curr Opin Neurobiol 13(1):70–78
35. Bargmann CI, Hartwieg E, Horvitz HR (1993) Odorant-selective genes and neurons mediate olfaction in C. elegans. Cell 74(3):515–527
36. Zamberlan DC, Arantes LP, Machado ML, Golombieski R, Soares FAA (2014) Diphenyl-diselenide suppresses amyloid-β peptide in Caenorhabditis elegans model of Alzheimer’s disease. Neuroscience 278:40–50
37. Lewis JA, Fleming JT (1995) Basic culture methods. Methods Cell Biol 48:3–29
38. Ura K, Kai T, Sakata S, Iguchi T, Arizono K (2002) Aquatic acute toxicity testing using the nematode Caenorhabditis elegans. J Health Sci 48(6):583–586
39. Hanukoglu I, Tanese N, Fuchs E (1983) Complementary DNA sequence of a human cytoplasmic actin: interspecies divergence of 3′ non-coding regions. J Mol Biol 163(4):673–678
40. Gunning PW, Ghoshdastider U, Whitaker S, Popp D, Robinson RC (2015) The evolution of compositionally and functionally distinct actin filaments. J Cell Sci 128(11):2009–2019
41. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 (9)
42. de Jong WW, Caspers GJ, Leunissen JA (1998) Genealogy of the α-crystallin—small heat-shock protein superfamily. Int J Biol Macromol 22(3–4):151–162
43. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, Sahagan BG (2003) Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer’s disease model. Neurobiol Aging 24(3):397–413
44. Fonte V, Kapulkin V, Taft A, Fluet A, Friedman D, Link CD (2002) Interaction of intracellular β amyloid peptide with chaperone proteins. Proc Natl Acad Sci USA 99(14):9439–9444
45. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11(3):213–228
46. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF (2005) Soluble β-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25(48):11061–11070
47. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440(7082):352–357
48. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM (2006) Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease—a link between Aβ and tau pathology. J Biol Chem 281(3):1599–1604